List of Venlafaxine Besylate drug patents

Venlafaxine Besylate is owned by Almatica.

Venlafaxine Besylate contains Venlafaxine Besylate.

Venlafaxine Besylate has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Venlafaxine Besylate are:

  • US6717015

Venlafaxine Besylate was authorised for market use on 29 June, 2022.

Venlafaxine Besylate is available in tablet, extended release;oral dosage forms.

Venlafaxine Besylate can be used as treatment of depression and generalized anxiety disorder.

The generics of Venlafaxine Besylate are possible to be released after 16 May, 2028.

VENLAFAXINE BESYLATE Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6717015 ALMATICA Venlafaxine besylate
Mar, 2023

(2 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7776358 ALMATICA Extended release venlafaxine besylate tablets
May, 2028

(4 years from now)

Do you want to check out VENLAFAXINE BESYLATE patents from before 2022?

Drugs and Companies using VENLAFAXINE BESYLATE ingredient

Market Authorisation Date: 29 June, 2022

Treatment: Treatment of depression and generalized anxiety disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

VENLAFAXINE BESYLATE family patents

4

United States

2

European Union

1

South Africa

1

Argentina

1

Australia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in